Online inquiry

IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4658MR)

This product GTTS-WQ4658MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets FGFR1 gene. The antibody can be applied in Non-alcoholic steatohepatitis (NASH) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001174063.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2260
UniProt ID P11362
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ4658MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11089MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MCS-110
GTTS-WQ6803MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ14311MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ13043MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ6472MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CT-P-59
GTTS-WQ4164MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI-754111
GTTS-WQ93MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 1121B
GTTS-WQ6957MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ESBA-1008
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW